Use of versant™ TMA and bDNA 3.0 assays to detect and quantify hepatitis C virus in semen

✍ Scribed by Vyacheslav A. Pekler; Wendie A. Robbins; Adeline Nyamathi; Tatyana L. Yashina; Barbara Leak; Terry A. Robins

• Publisher: John Wiley and Sons
• Year: 2003
• Tongue: English
• Weight: 103 KB
• Volume: 17
• Category: Article
• ISSN: 0887-8013
• DOI: 10.1002/jcla.10107

✦ Synopsis

Abstract

Previous findings of hepatitis C virus (HCV) in human semen have been inconsistent. This study attempted to elucidate the presence of HCV in semen from 80 HCV RNA blood plasma positive homeless men using two novel non‐PCR based techniques. Semen was frozen immediately upon ejaculation in order to preserve virus quantity. This study demonstrated that 36% of the study population had HCV in semen. Bayer's Versant™ HCV RNA Qualitative Assay (Bayer Diagnostics, Emeryville, CA) based on transcription mediated amplification (TMA) assay detected 29 positive semen samples and Versant™ HCV RNA 3.0 Assay (bDNA) (Bayer Diagnostics, Emeryville, CA) detected only six. This demonstrated that TMA was more sensitive than the bDNA in detecting HCV in semen (P<0.002). HCV blood plasma viral load was positively correlated with the presence of HCV in semen (Spearman's Rho=0.40, P<0.0002), while the presence of leukocytes in semen was not (Spearman's Rho=0.19, P<0.12). This supports the hypothesis that HCV is “leaked out” from the peripheral circulation into semen. Three semen samples had a viral load of >5,000 IU/mL. The presence of a high viral load in semen in certain men suggests that sexual transmission of the virus is possible. Laboratory capability to accurately detect HCV positive semen is an important step in establishing the risk of sexual transmission and in identifying strategies for protecting uninfected partners. J. Clin. Lab. Anal. 17:264–270, 2003. © 2003 Wiley‐Liss, Inc.